Open access

Association of Haemostasis Activation Markers with Thrombophilia and Venous Thromboembolism

Written By

Tjaša Vižintin-Cuderman, Mojca Božič-Mijovski, Aleksandra Antović, Polona Peternel, Matija Kozak and Mojca Stegnar

Submitted: 07 February 2011 Published: 09 November 2011

DOI: 10.5772/26357

From the Edited Volume


Edited by Andrea Luigi Tranquilli

Chapter metrics overview

2,319 Chapter Downloads

View Full Metrics

1. Introduction

Thrombophilia (TF) is defined as an inherited or acquired tendency to develop thrombosis. TF creates a state of hypercoagulability, i.e. haemostasis activation without actual clot formation which can be detected in vitro by specific laboratory techniques. Thrombosis as a clinical phenomenon, however, only occurs when the balance between pro-coagulant and anti-coagulant elements of haemostasis is disrupted to such an extent that it leads to clot formation in the circulating blood.

TF is most commonly associated with an increased risk of thrombosis in the venous system, i.e. venous thromboembolism (VTE). VTE is a common disease with an annual incidence of about 1 case per 1000 person-years and is a cause of substantial morbidity and mortality worldwide (White, 2003). Furthermore, it is a chronic disease that often recurs. A third of patients with first VTE, experience a recurrence within the next 5 to 8 years. Recurrence is best prevented since it is fatal in 5 % of patients and late sequelae, such as post-thrombotic syndrome, are also very common (Schulman et al, 2006). The standard treatment for acute VTE (unfractionated or low-molecular-weight heparin, followed by vitamin K antagonists for at least several months) reduces the risk of recurrence by 80 to 90 % (Kearon et al, 2008). Although ideally all patients should receive long-term treatment with vitamin K antagonists to reduce the risk of recurrence, one has to bear in mind the 2 -3 % annual incidence of major bleeding on anticoagulant treatment (Ansell et al, 2008). The duration of anticoagulant treatment should therefore be tailored individually to optimize the preventive action of treatment with the minimum risk of bleeding. The likelihood of recurrence varies among individuals and is strongly influenced by the presence of clinical risk factors. Patients whose first VTE was triggered by a circumstantial risk factor (provoked VTE) have a lower risk of recurrence than patients whose event was unprovoked (idiopathic VTE), or who carry persistent risk factors (Kearon et al, 2008). It is, however, arguable whether the level of risk estimated from clinical risk factors alone justifies long-term anticoagulation.

For a long time it was thought that screening for TF, a persistent risk factor for VTE, would facilitate clinical decision-making in determining the duration of anticoagulant treatment. Over the past decades knowledge of TF has increased substantially, as did the number of individuals screened for TF. It was shown that when all known TF defects are considered, TF is found in about half of patients with the first VTE (Christiansen et al, 2005). However, routine TF screening is usually limited to those TF defects that carry a strong to moderate risk of VTE: antithrombin, protein C and protein S deficiencies, factor V Leiden, prothrombin G20210A mutation (inherited defects) and antiphospholipid antibodies (acquired defects). Testing for other TF defects, such as hyperhomocysteinaemia, high fibrinogen, increased factors VIII, IX, XI, dysfibrinogenaemia, reduced tissue factor pathway inhibitor and factor XIII polymorphisms is usually only performed in clinical studies (Stegnar, 2010).

TF status does not directly translate into an increased risk of either first or recurrent VTE (Christiansen et al, 2005). First of all, there is considerable variation in the magnitude of risk associated with different TF defects. Furthermore, the magnitude of risk a specific TF defect carries is not the same for first or for recurrent VTE. The most common TF defects, such as factor V Leiden and prothrombin G2021A mutation, carry a modest risk of both first and recurrent VTE (Ho et al, 2006). The rarely occurring deficiencies of antithrombin, protein C and protein S, historically believed to be very strong risk factors for first VTE, convey only a slightly higher risk for recurrence than factor V Leiden and prothrombin G2021A mutation (Christiansen et al, 2005, De Stefano et al, 2006).

The results of TF screening actually alter the clinical management only in selected groups of VTE patients (Stegnar, 2010). Moreover, since VTE is a multi-causal disease, there are usually other factors apart from TF that contribute to the development of VTE (Rosendaal 1999). It seems therefore that to assess VTE risk in individuals with TF an additional tool is needed. The aim of this article is to review the available evidence as to whether screening for hypercoagulability could represent such a tool.


2. Activation of haemostasis

The initial events in haemostasis involve activation of the endothelium and blood cells in response to vessel wall injury, which results in release of a variety of soluble factors involved in the control of haemostasis and cell adhesion. In this review, cell adhesion will be limited merely to cell adhesion molecules P-selectin, E-selectin, vascular cell adhesion molecule 1 (VCAM-1) and intercellular cell adhesion molecule 1 (ICAM-1) that mediate in the binding of endothelium and blood cells.

Blood coagulation is initiated by the release of tissue factor from activated endothelial and blood cells. Activated endothelial cells and platelets express P-selectin, which binds monocytes and macrophages. Bound monocytes and macrophages expose tissue factor to the circulation. Tissue factor forms a complex with circulating activated factor VII. This complex activates factor X to activated factor X (Xa) and factor Xa converts minor quantities of prothrombin into thrombin. In this process, prothrombin fragments 1+2 (F1+2) are released. These events are regulated by tissue factor pathway inhibitor, which neutralizes factor Xa and by antithrombin, which inactivates thrombin by forming thrombin-antithrombin (TAT) complexes. When the threshold level of thrombin is generated, thrombin activates platelets, as well as factors XIII, V, VIII and XI to augment its own generation. This is achieved by further conversion of factor X to factor Xa, using activated factors VIII and IX as cofactors. Factor Xa together with activated factor V (prothrombinase complex) converts the majority of prothrombin into thrombin. These events are regulated by activated protein C and its cofactor protein S, which neutralize activated factors V and VIII and so limit thrombin generation (Monroe & Hoffman, 2006).

Thrombin cleaves fibrinogen and fibrinopeptides A and B are released from alpha and beta polypeptide chains of fibrinogen. The resulting fibrin monomers polymerise to form soluble non-cross-linked fibrin, which is then cross-linked by activated factor XIII. The formation of fibrin triggers activation of the fibrinolytic system. Tissue-type plasminogen activator (t-PA), which is released by endothelial cells, activates plasminogen to plasmin. Plasmin degrades fibrin to fibrin degradation products of various molecular sizes. D-dimer, the smallest of the fibrin degradation products, retains the cross-links of the original fibrin. These events are regulated by several inhibitors of fibrinolysis: plasminogen activator inhibitors type 1 and 2 (PAI-1 and PAI-2), antiplasmin and thrombin activatable fibrinolysis inhibitor (Rijken & Lijnen, 2009).


3. Laboratory methods to detect activation of haemostasis

Activation of haemostasis (hypercoagulability) is ideally detected prior to the appearance of thrombotic phenomena. Laboratory recognition of hypercoagulability is, however, a very demanding task due to the complexity of the haemostatic system. It can be detected by global tests (global haemostasis screening assays) that provide an overview of the entire haemostatic system, including enzymes, cofactors and inhibitors. Another approach to detecting hypercoagulability is to measure specific substances (peptides, enzymes, enzyme-inhibitor complexes) that are liberated with activation of the coagulation and fibrinolysis systems in vivo (specific markers of haemostasis activation). The most recent method to assess hypercoagulability is to detect molecules that are released from activated endothelial and blood cells in response to injury of the vessel wall (markers of endothelial and platelet activation).

3.1. Global haemostasis screening assays

Activated partial thromboplastin time (aPTT) has been in use for more than half a century (Langdell et al, 1953). It is simple and the most widely used global haemostasis screening assay, sensitive to all coagulation factors except factor VII. The end-point of this assay is the formation of a fibrin clot, detected manually or automatically by measuring the optical density of plasma after addition of phospholipids and a surface activator such as celite. Clotting occurs when 3 – 5 % of the total amount of thrombin is produced (Brummel et al, 2002) and therefore subsequent haemostatic responses or possible abnormalities of the haemostatic process cannot be observed (Mann et al, 2003). Nonetheless, a strong association was found between shortened aPTT and increased risk of first (Tripodi et al, 2004) and recurrent VTE (Hron et al, 2006; Legnani et al, 2006). The increase in VTE risk was independent of TF status. Shortening of aPTT might be due to increased concentrations of factors VIII, IX and XI Legnani et al, 2006).

Thromboelastography (TEG) monitors haemostasis as a dynamic process, evaluating both clotting, fibrinolysis and platelet function. TEG variables are derived from a trace produced from measurement of the viscoelastic changes associated with clot formation and degradation (Sorensen et al, 2003).

Whilst the whole blood sample in a TEG cuvette remains liquid, the motion of the cuvette does not affect a pin which is suspended freely from a torsion wire. However, when the clot starts to form, the fibrin strands “couple” the motion of the cup to the motion of the pin, which is amplified and recorded. Several variables of the recording can be evaluated such as the reaction time, angle formed by the slope of the TEG trace, maximum amplitude and clot lysis index (Mallet & Cox, 1992).

TEG as a tool to measure hypercoagulability in the setting of VTE was only assessed in small studies. TEG showed a marked hypercoagulable profile in patients with acute VTE (Spiezia et al, 2008). Also in patients with a history of venous or arterial thrombosis, shorter clotting times and accelerated maximum velocity of clot propagation were measured (Hvitfeldt Poulsen et al, 2006). However, another study in patients with a history of cerebral vein thrombosis did not confirm these results (Koopman et al, 2009). TF, present in approximately half of the patients in these studies, did not influence TEG parameters. Similarly, in individuals with a personal or family history of VTE, hypercoagulable TEG was measured in 40 % of patients, but it did not correlate with TF status (O’Donnell et al, 2004). TEG therefore cannot be used as a screening test for TF, but it might be a useful adjunctive test, particularly in patients without known TF defects. Further studies are needed to determine whether TEG can be used to predict the recurrence of thrombotic events.

However, TEG is poorly standardized, has a high coefficient of variation and is influenced by many pre-analytical variables, which makes it less suitable for routine clinical use to assess hypercoagulability (Chen & Teruya, 2009). Besides, it is a whole blood assay and therefore frozen-thawed samples cannot be used.

Thrombin generation assay (TGA) reflects the potential of plasma to generate thrombin following in vitro activation of coagulation with tissue factor or other trigger (Hemker et al, 2002). The thrombin concentration is continuously monitored by adding a suitable thrombin substrate and formation of split products is detected by optical densitometry or fluorometry. The resulting thrombin generation curve and its three most important parameters of lag time, peak value and area under the curve or endogenous thrombin potential, reflect and integrate all pro- and anticoagulant reactions that regulate the formation and inhibition of thrombin (van Veen et al, 2008). However, TGA does not measure the final step of coagulation, i.e. fibrin formation. TGA is performed in plasma, is commercially available and relatively easy to use. It is, however, not standardized; it is influenced by many pre-analytical variables and there is a high inter-laboratory variability due to different reagents and their concentrations, making it difficult to establish reference ranges (Castoldi & Rosing 2011).

Thrombin generation is elevated in antithrombin deficiency (Wielders et al, 1997, Alhenc-Gelas et al, 2010), protein S deficiency (Castoldi et al, 2010), protein C deficiency (Hezard et al, 2007), in carriers of factor V Leiden (Hezard et al, 2006, Lincz et al, 2006) and prothrombin G202010 mutation (Kyrle et al, 1998, Lavigne-Lissalde et al, 2010). It is also associated with the presence of antiphospholipid antibodies (Liestol et al, 2007, Devreese et al, 2009) and increased levels of factors VIII (ten Cate-Hoek et al, 2008), IX and XI (Siegemund et al, 2004).

Elevated thrombin generation was also investigated as a risk factor for the first VTE event and its recurrence. It was shown that elevated thrombin generation was associated with a 1.7 fold increased risk of first idiopathic VTE (van Hylckama Vlieg et al, 2007). The association between elevated thrombin generation and the risk of first VTE was confirmed in several other studies (Dargaud et al, 2006, Lutsey et al, 2009, Wichers et al, 2009). Furthermore, elevated thrombin generation identifies patients at risk of VTE recurrence. In one cohort it was shown that patients with low levels of thrombin generation after discontinuation of anticoagulant treatment had an almost 60 % lower risk of recurrence compared to patients with elevated thrombin generation (Hron et al, 2006). Subsequent studies have confirmed that patients at high risk of VTE recurrence can be identified by TGA (Hron et al, 2006, Tripodi et al, 2008, Besser et al, 2008, Eichinger et al, 2008).

Overall haemostasis potential (OHP) is based on repeated spectrophotometric registration of fibrin formation in two parallel samples of citrated plasma, to which small amounts of thrombin and t-PA (the first plasma sample) or only thrombin (the second plasma sample) are added. The areas under the fibrin formation curves obtained represent OHP (the first plasma sample with thrombin and t-PA) and overall coagulation potential (OCP, the second plasma sample with only thrombin added). Overall fibrinolytic potential (OFP) is calculated as the difference between OHP and OCP (He et al, 2001). The OHP assay is not commercially available and it is not yet standardized. It is, however, inexpensive, easy and fast to perform (Antović, 2008).

OHP has been shown to detect hypercoagulability in smaller studies. Increased OHP was found in 75 % of women with a history of pregnancy-provoked VTE. In women with concomitant TF (acquired activated protein C resistance or factor V Leiden) imbalance in haemostatic potential was more severe, since OHP was increased in all women (Antović et al, 2003). In another study, OHP also identified the hypercoagulable state in patients with lupus anticoagulants and a history of thrombotic events, regardless of concomitant anticoagulant therapy (Curnow et al, 2007). Using a modification of the original OHP assay (the coagulation inhibitor potential CIP assay), severe TF (deficiencies of antithrombin, protein C and protein S, homozygosity for factor V Leiden and combinations) could be detected with a sensitivity of 100 % and specificity of 70 - 80% (Andresen et al, 2002, 2004).

OHP was also studied during anticoagulant treatment for VTE. In a study of 70 patients with acute venous thrombosis given standard anticoagulant treatment (low-molecular-weight heparin followed by warfarin), OHP was significantly increased before treatment and greatly decreased during combined treatment with heparin and warfarin (overlapping period), while during warfarin only treatment OHP was about half that before treatment. After cessation of therapy, OHP values increased but remained lower than in the pre-treatment period. OHP levels did not differ between patients with or without TF (Vižintin-Cuderman et al, to be published).

3.2. Specific markers of haemostasis activation

F1+2 and TAT are markers of in vivo activity of factor X and thrombin. They are liberated during activation and generation of thrombin and are stable enough to be detected by laboratory methods, mainly enzyme-linked immunosorbent assays. However, they are extremely sensitive to in vitro artefacts. The quality of the sample and the reliability of the result depend on the technique of blood sampling and the experience of the person performing the procedure (Stegnar et al, 2007). Besides blood sampling, the different reagents used as well as the preparation and storage of the samples can influence the results (Greenberg et al 1994, Miller et al, 1995). Consequently, they are rarely used today. However, around twenty years ago they were tested in various small studies that gave contradictory results.

Increased F1+2 was found in individuals with antithrombin, protein C and S deficiencies (Demers et al, 1992, Mannucci et al, 1992), as well as in those with activated protein C (APC) resistance (Simioni et al, 1996, Bauer et al, 2000), prothrombin G20210A mutation (Bauer et al, 2000) antiphospholipid syndrome (Ames et al, 1996), hyperhomocysteinemia (Kyrle et al, 1997a) and increased levels of factor VIII (O’Donnell et al, 2001). Not all studies, however, confirmed the association of increased F1+2 levels with TF (Kyrle et al, 1998, Eichinger et al, 1999, Lowe et al, 1999).

TAT was increased in association with increased factor VIII levels (O’Donnell et al, 2001) and also with APC resistance in one study (Simioni et al, 1996), but not in two others (Eichinger et al, 1999, Lowe et al, 1999). Similarly, increased TAT was not associated with antithrombin (Demers et al, 1992), protein C and S deficiencies (Macherel et al, 1992) or with antiphospholipid syndrome (Ames et al, 1996).

In patients with acute VTE, F1+2 and TAT are elevated and normalize 2 to 4 days after introduction of heparin treatment (The DVTENOX study group, 1993, Stricker et al, 1999, Peternel et al, 2000). The levels of these markers remain low also during treatment with warfarin (Elias et al, 1993, Jerkemann et al, 2000, Vižintin-Cuderman et al, to be published). TF does not seem to influence F1+2 and TAT levels either during anticoagulant treatment or after its withdrawal (Cuderman et al, 2007, Vižintin-Cuderman et al, to be published).

There are few studies on the utility of these markers in assessing VTE recurrence risk. In two studies F1+2 was not associated with recurrence in patients with a history of VTE (Kyrle et al, 1997b, Vižintin-Cuderman et al, to be published). Two recent studies, however, showed that in patients with VTE increased F1+2 measured 1 month after withdrawal of anticoagulant treatment was associated with increased risk of recurrent thrombosis, irrespective of TF status (Poli, 2008, 2010).

D-dimer is a degradation product of cross-linked fibrin. It is marker of both activated coagulation and fibrinolysis. D-dimer is best known today as the biochemical gold standard for initial assessment of suspected VTE. It has a sensitivity of up to 95 % and a negative predictive value of nearly 100 % (Di Nisio et al, 2007) and is an integral part of diagnostic algorithms to exclude VTE (Righini et al, 2008).

In patients with acute VTE, D-dimer is elevated and decreases after 1 to 3 days of treatment, but remains above normal levels for at least the first week of treatment (The DVTENOX study group, 1993, Stricker et al, 1999, Peternel et al, 2002). This is probably due to prolonged fibrinolysis, which is independent of heparin therapy and thrombin generation, but it may also be partly due to the relatively long half-life of D-dimer (Mannucci, 1994). By the first month of treatment, D-dimer levels mostly return to normal and remain so throughout warfarin treatment (Elias et al, 1993, Meissner et al, 2000, Vižintin-Cuderman et al, to be published). One study showed that during anticoagulant treatment in patients with TF, D-dimer levels remain higher than in patients without TF, albeit not significantly (Vižintin-Cuderman et al, to be published). After discontinuation of anticoagulant treatment, D-dimer levels in patients with TF remain higher than in those without TF (Palareti et al, 2003, Vižintin-Cuderman et al, to be published).

D-dimer was also investigated as a risk factor of the first VTE event and its recurrence. In a population-based cohort study, D-dimer was associated with a 3–fold increased risk of the first VTE event (Cushman et al, 2003) and with a 2.2 – 3–fold increased risk of recurrent VTE (Andreescu et al, 2002; Palareti et al, 2003, Cosmi et al, 2005).

Moreover, D-dimer is a marker for predicting VTE recurrence after cessation of anticoagulant treatment (Verhovsek et al, 2008). Normal levels of D-dimer one month after cessation of anticoagulant treatment have been shown to have a high negative predictive value for VTE recurrence (Palareti et al, 2002, Eichinger et al, 2003). These results were tested in an interventional study in patients with unprovoked VTE. It was shown that elevated D-dimer one month after cessation of anticoagulant treatment significantly increases the risk of recurrent VTE, which can be reduced by resumption of anticoagulant therapy (Palareti et al, 2006). Interestingly, it was demonstrated that in patients with TF who have elevated D-dimer levels one month after cessation of anticoagulant treatment, the risk of recurrence is particularly high in comparison to patients with TF who have normal D-dimer. The difference was particularly important in carriers of common TF defects, such as factor V Leiden and prothrombin G20210A mutation (Palareti et al, 2003).

Surprisingly, there are few studies on the association of D-dimer with specific TF defects. Elevated D-dimer was found in carriers of factor V Leiden (Eichinger et al, 1999, Cuderman et al, 2007) and in the presence of antiphospholipid antibodies (Ames et al, 1996).

3.3. Markers of endothelial and platelet activation

P-selectin is a cell adhesion molecule that is expressed by platelets and endothelial cells upon their activation and is partly released in plasma in its soluble form. It can be measured in plasma by an enzyme-linked immunosorbent assay.

P-selectin levels are increased in acute VTE (Smith et al, 1999, Božič et al, 2002, Rectenwald et al, 2005, Ramacciotti et al, 2011). When P-selectin was tested as a possible marker for diagnosis of VTE, it was shown that a combination of the clinical prediction score and low P-selectin can be used to exclude VTE with a sensitivity and specificity similar to that of D-dimer. In addition, the combination of the clinical prediction score and high P-selectin has, unlike D-dimer, a very high positive predictive value in confirming acute VTE (Rectenwald et al, 2005, Ramacciotti et al, 2011).

After commencement of anticoagulant treatment for VTE, P-selectin levels decrease. A small study showed a decrease in P-selectin levels after 7 days of treatment with unfractionated heparin (Papalambros et al, 2004). In a study of 70 patients receiving low-molecular-weight heparin followed by warfarin, P-selectin levels decreased already after 3 days of treatment. Interestingly, one month after treatment discontinuation, P-selectin levels were not significantly higher than during treatment (Vižintin-Cuderman et al, to be published). Similarly, in another study there was no difference in P-selectin levels between patients receiving warfarin and those without anticoagulant therapy (Ay et al, 2007).

In patients with a history of VTE, elevated P-selectin is associated with increased risk of recurrence. Two case-control studies found that in patients at least 3 months after the onset of acute VTE, P-selectin levels were elevated compared to healthy controls (Blann et al, 2000; Ay et al, 2007). This result was confirmed in two prospective cohort studies that investigated P-selectin as a predictive marker for recurrence in patients with VTE (Kyrle et al, 2007, Vižintin-Cuderman et al, to be published). Similarly in another prospective cohort study, elevated P-selectin was a predictor of the occurrence of VTE in cancer patients (Ay et al, 2008).

There is not much evidence, however, on P-selectin levels in relation to specific TF defects. In a small study it was shown that P-selectin is elevated in patients with lupus anticoagulants and a history of VTE (Bugert et al, 2007). The presence of TF did not influence P-selectin levels during and after anticoagulant treatment in another study (Vižintin-Cuderman et al, to be published). Finally, TF status did not have any influence on P-selectin as a risk factor of VTE recurrence (Kyrle et al, 2007).

The association of other markers of endothelial and platelet activation (E-selectin, VCAM-1, ICAM-1, t-PA and PAI-1) with TF and VTE is poorly investigated. In a small study, E-selectin, VCAM-1 and ICAM-1 were not shown to be elevated in acute VTE (Bucek et al, 2003). However, elevated VCAM-1 levels were found in patients with acute VTE in two earlier studies (Smith et al, 1999, Božič et al, 2002). Elevated PAI-1 and t-PA levels were associated with increased risk of first or recurrent VTE in some studies (Schulman & Wiman, 1996, Meltzer et al, 2010), but not in others (Crowther et al, 2001, Folsom et al, 2003). The influence of TF on t-PA and PAI-1 levels was addressed in two small studies in patients with a history of VTE. No difference was found between patients with factor V Leiden (Stegnar et al, 1997) or hyperhomocysteinemia (Božič et al, 2000) and patients without these TF defects.


4. Conclusions

Assessment of haemostasis activation (hypercoagulability) is a very demanding task due to the complexity of the haemostatic system. However, it can be achieved either by global haemostasis screening assays that provide an overview of the entire haemostatic system, including enzymes, cofactors and inhibitors, or alternatively, by measuring specific haemostasis activation markers - peptides, enzymes or enzyme-inhibitor complexes that are liberated with the activation of coagulation, fibrinolysis, endothelial cells and platelets in vivo. Two global haemostasis screening assays (aPTT and TEG) have been used for many years, albeit their usefulness in detecting hypercoagulability and the risk of first and recurrent VTE seems to be limited due to insufficient clinical data, lack of standardization and the influence of pre-analytical factors. TGA and OHP are more promising. Both assays seem to be sensitive to TF defects and to be associated with the risk of VTE. Apart from D-dimer, other specific haemostasis activation markers, namely F1+2 and TAT, are extremely sensitive to in vitro artefacts and are rarely used today. However, around twenty years ago they were tested in various small studies that gave contradictory results. D-dimer is more robust and clinically useful for excluding VTE and also for detecting the risk of VTE after discontinuation of anticoagulant treatment. The risk of recurrence seems to be particularly high in patients with common TF defects, such as factor V Leiden and prothrombin G20210A mutation and high D-dimer. Finally, it has been shown that P-selectin, a marker of endothelial and platelet activation, can be used to exclude VTE with sensitivity and specificity similar to that of D-dimer. However, there is not much evidence on the association of P-selectin with specific TF defects.


  1. 1. Alhenc-Gelas M. Canonico M. Picard V. 2010 Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost, 8 4 (Apr 2010), 845 848
  2. 2. Ames P. R. Tommasino C. Iannaccone L. Brillante M. Cimino R. Brancaccio V. 1996 Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies- a crucial role for acquired protein S deficiency. Thromb Haemost, 76 2 (Aug 1996), 190 194
  3. 3. Andreescu A. C. Cushman M. Rosendaal F. R. 2002 D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost, 87 1 (Jan 2002), 47 51
  4. 4. Andresen M. S. Iversen N. Abildgaard U. 2002 Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin. Thromb Res, 108 5-6 , (Dec 2002), 323 328
  5. 5. Andresen M. S. Abildgaard U. Liestøl S. Sandset P. M. Mowinckel M. C. Ødegaard O. R. Larsen M. L. Diep M. L. 2004 The ability of three global plasma assays to recognize thrombophilia. Thromb Res, 113 6 (2004), 411 417
  6. 6. Ansell J. Hirsh J. Hylek E. Jacobson A. Crowther M. Palareti G. American College. of Chest. Physicians 2008 Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133 6 Suppl, (Jun 2008), 160S 198S
  7. 7. Antović A. Blombäck M. Bremme K. Van Rooijen M. He S. 2003 Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance J Thromb Haemost, 1 12 (Dec 2003), 2531 2535
  8. 8. Antović A. 2008 Screening haemostasis- looking for global assays: the overall haemostasis potential (OHP) method- a possible tool for laboratory investigation of global haemostasis in both hypo- and hypercoagulable conditions. Curr Vasc Pharm, 6 3 (Jul 2008), 173 185
  9. 9. Ay C. Jungbauer L. V. Sailer T. Tengler T. Koder S. Kaider A. Panzer S. Quehenberger P. Pabinger I. Mannhalter C. 2007 High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem, 53 7 (Jul 2007), 1235 1243
  10. 10. Ay C. Simanek R. Vormittag R. Dunkler D. Alguel G. Koder S. Kornek G. Marosi C. Wagner O. Zielinski C. Pabinger I. 2008 High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 112 7 (Oct 2008), 2703 2708
  11. 11. Bauer K. A. Humphries S. Smillie B. Li L. Cooper J. A. Barzegar S. Rosenberg R. G. Miller G. J. 2000 Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost, 84 3 (Sep 2000), 396 400
  12. 12. Besser M. Baglin C. Luddington R. van Hylckama Vlieg. A. Baglin T. 2008 High rate of unprovoked recurrent venous thrombosis is associated with high thrombin generating potential in a prospective cohort study. J Thromb Haemost, 6 10 (Oct 2008), 1720 1725
  13. 13. Blann A.D. Noteboom WMP Rosendaal F. R. 2000 Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol, 108 1 (Jan 2000), 191 193
  14. 14. Božič M. Stegnar M. Fermo I. Ritonja A. Peternel P. Stare J. D’Angelo A. 2000 Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. Thromb Res, 100 4 (Nov 2000), 271 278
  15. 15. Božič M. Blinc A. Stegnar M. 2002 D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis. Thromb Res, 108 2-3 , (Nov 2002), 107 114
  16. 16. Brummel K. E. Paradis S. G. Butenas S. Mann K. G. 2002 Thrombin functions during tissue factor induced blood coagulation. Blood, 100 1 (Jul 2002), 148 152
  17. 17. Bucek R. A. Reiter M. Quehenberger P. Minar E. Baghestanian M. 2003 The role of soluble cell adhesion molecules in patients with suspected deep vein thrombosis. Blood Coagul Fibrinolysis, 14 7 (Oct 2003), 653 657
  18. 18. Bugert P. Pabinger I. Stamer K. Vormittag R. Skeate R. C. Wahi M.M. Panzer S. 2007 The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. Thromb Haemost, 97 4 (Apr 2007), 573 580
  19. 19. Castoldi E. Maurissen L. F. Tormene D. Spiezia L. Gavasso S. Radu C. Hackeng T. M. Rosing J. Simioni P. 2010 Similar hypercoagulable states and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica, 95 9 (Sep 2010), 1563 1571
  20. 20. Castoldi E. Rosing J. 2011 Thrombin generation tests. Thromb Res, 127 Suppl 3, (Feb 2011), S21 S25
  21. 21. Chen A. Teruya J. 2009 Global hemostasis testing thromboelastography: old technology, new applications. Clin Lab Med, 29 2 (Jun 2009), 391 407
  22. 22. Christiansen S. C. Cannegieter S. C. Koster T. Vandenbroucke J. P. Rosendaal F. R. 2005 Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA, 293 19 (May 2005), 2352 2361
  23. 23. Cosmi B. Legnani C. Cini M. Guazzaloca G. Palareti G. 2005 D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost, 94 5 (Nov 2005), 969 974
  24. 24. Crowther M.A. Roberts J. Roberts R. Johnston M. Stevens P. Skingley P. Patrassi G. M. Sartori M. T. Hirsh J. Prandoni P. Weitz J. I. Gent M. Ginsberg J. S. 2001 Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost, 85 3 (Mar 2001), 390 394
  25. 25. Cuderman T. V. Božič M. Peternel P. Stegnar M. 2008 Hemostasis activation in thrombophilic subjects with or without a history of venous thrombosis. Clin Appl Thromb Hemost, 14 1 (Jan 2008), 55 62
  26. 26. Curnow J. L. Morel-Kopp M. C. Roddie C. Aboud M. Ward C. M. 2007 Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost, 5 3 (Mar 2007), 528 534
  27. 27. Cushman M. Folsom A. R. Wang L. Aleksic N. Rosamond W. D. Tracy R. P. Heckbert S. R. 2003 Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood, 101 4 (Feb 2003), 1243 1248
  28. 28. Dargaud Y. Trzeciak M. C. Bordet J. C. Ninet J. Negrier C. 2006 Use of calibrated automated thrombinography +/− thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost, 96 5 (Nov 2006), 562 567
  29. 29. Demers C. Ginsberg J. S. Henderson P. Ofusu F. A. Weitz J. I. MA Blajchman 1992 Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost, 67 5 (May 1992), 542 544
  30. 30. De Stefano V. Simioni P. Rossi E. Tormene D. Za T. Pagnan A. Leone G. 2006 The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica, 91 5 (May 2006), 695 698
  31. 31. Devreese K. Peerlinck K. Arnout J. Hoylaerts M. F. 2009 Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost, 101 1 (Jan 2009), 185 196
  32. 32. Di Nisio M. Squizzato A. Rutjes A. W. Büller H. R. Zwinderman A. H. Bossuyt P. M. 2007 Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost, 5 2 (Feb 2007), 296 304
  33. 33. Eichinger S. Weltermann A. Philipp K. Hafner E. Kaider A. Kittl E. M. Brenner B. Mannhalter C. Lechner K. Kyrle P. A. 1999 Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost, 82 4 (Oct 1999), 1232 1236
  34. 34. Eichinger S. Minar E. Bialonczyk C. Hirschl M. Quehenberger P. Schneider B. Weltermann A. Wagner O. Kyrle P. A. 2003 D-dimer levels and risk of recurrent venous thromboembolism. JAMA, 290 8 (Aug 2003), 1071 1074
  35. 35. Eichinger S. Hron G. Kollars M. Kyrle P. A. 2008 Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem, 54 12 (Dec 2008), 2042 2048
  36. 36. Elias A. Bonfils S. Daoud-Elias M. Gauthier B. Sié P. Boccalon H. Boneu B. 1993 Influence of long term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombinIII complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost, 69 4 (Apr 1993), 302 305
  37. 37. Folsom A. R. Cushman M. Heckbert S. R. Rosamond W. D. Aleksic N. 2003 Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol, 56 6 (Jun 2003), 598 603
  38. 38. Greenberg C.S. Hursting M.J. Macik B. G. Ortel T. L. Kane W.H. Moore B.M. 1994 Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem, 40 10 (Oct 1994), 1962 1969
  39. 39. He S. Antović A. Blombaeck M. 2001 A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories and research work. Thromb Res, 103 5 (Sep 2001), 355 361
  40. 40. Hemker H. C. Giesen P. Al Dieri. R. Regnault V. de Smed E. Wagenvoord R. Lecompte T. Béguin S. 2002 The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Patophysiol Haemost Thromb, 32 5-6 , (Sep-Dec 2002), 249 253
  41. 41. Hézard N. Bouaziz-Borgi L. Remy M. G. Florent B. Nguyen P. 2007 Protein C deficiency screening using a thrombin-generation assay. Thromb Haemost, 97 1 (Jan 2007), 165 166
  42. 42. Hézard N. Bouaziz-Borgi L. Remy M. G. Nguyen P. 2006 Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem, 52 4 (Apr 2006), 665 670
  43. 43. Ho W.K Hankey G.J. Quinlan D. J. Eikelboom J.W. 2006 Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, 166 7 (Apr 2006), 729 736
  44. 44. Hron G. Eichinger S. Weltermann A. Quehenberger P. Halbmayer W. M. Kyrle P. A. 2006 Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost, 4 4 (Apr 2006), 752 756
  45. 45. Hvitfeldt Poulsen. L. Christiansen K. Sørensen B. Ingerslev J. 2006 Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest, 66 4 (2006), 329 336
  46. 46. Jerkeman A. Astermark J. Hedner U. Lethagen S. Olsson C. G. Berntorp E. 2000 Correlation between different intensities of anti-vitamin K treatment and coagulation parameters. Thromb Res, 98 6 (Jun 2000), 467 471
  47. 47. Kearon C. Kahn S. R. Agnelli G. Goldhaber S. Raskob G. E. Comerota A. J. AmericanCollege.ofChest.Physicians 2008 Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133 6 Suppl, (Jun 2008), 454S 545S
  48. 48. Koopman K. Uyttenboogaart M. Hendriks H. G. Luijckx G. J. Cramwinckel I. R. Vroomen P. C. De Keyser J. van der Meer J. 2009 Thromboelastography in patients with cerebral venous thrombosis. Thromb Res, 124 2 (Jun 2009), 185 188
  49. 49. Kyrle P. A. Stuempflen A. Hirschl M. Bialonczyk C. Herkner K. Speiser W. Weltermann A. Kaider A. Pabinger I. Lechner K. Eichinger S. 1997a Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost, 78 5 (Nov 1997), 1327 1331
  50. 50. Kyrle P. A. Eichinger S. Pabinger I. Stuempflen A. Hirschl M. Bialonczyk C. Schneider B. Mannhalter C. Melichart M. Traxler G. Weltermann A. Speiser W. Lechner K. 1997b Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost, 77 5 May 1997), 829 833
  51. 51. Kyrle P. A. Mannhalter C. Beguin S. Stuempflen A. Hirschl M. Weltermann A. Stain M. Brenner B. Speiser W. Pabinger I. Lechner K. Eichinger S. 1998 Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol, 18 8 (Aug 1998), 1287 1291
  52. 52. Kyrle P. A. Hron G. Eichinger S. Wagner O. 2007 Circulating P-selectin and the risk of recurrent venous thromboembolism. Thromb Haemost, 97 6 (Jun 2007), 880 883
  53. 53. Langdell R. D. Wagner R.H Brinkhous K.M. Wagner O. 1953 Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for haemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med, 41 4 (Apr 1953), 637 647
  54. 54. Lavigne-Lissalde G. Sanchez C. Castelli C. Alonso S. Mazoyer Bal Dit. Sollier C. Drouet L. Juhan-Vague I. Gris J. C. Alessi M. C. Morange P. E. 2010 Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost, 8 5 (May 2010), 942 949
  55. 55. Legnani C. Mattarozzi S. Cini M. Cosmi B. Favaretto E. Palareti G. 2006 Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol, 134 2 (Jul 2006), 227 232
  56. 56. Liestøl S. Sandset P. M. Mowinckel M. C. Wisløff F. 2007 Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost, 5 11 (Nov 2007), 2204 2210 .
  57. 57. Lincz L. F. Lonergan A. Scorgie F. E. Rowlings P. Gibson R. Lawrie A. Seldon M. 2006 Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. Pathophysiol Haemost Thromb, 35 6 (2006), 435 439
  58. 58. Lowe G. D. Rumley A. Woodward M. Reid E. Rumley J. 1991 Activated protein C resistance and the FV:R506Q mutation in a random population sample. Thromb Haemost, 81 6 (Jun 1991), 918 924
  59. 59. Lutsey P. L. Folsom A. R. Heckbert S. R. Cushman M. 2009 Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost, 7 10 (Oct 2009), 1639 1648
  60. 60. Macherel P. Sulzer I. Furlan M. Lammle B. 1992 Determination of thrombin-antithrombin-III-complex is not a suitable screening test for detecting deficiency of protein C or protein S. Thromb Res, 66 6 (Jun 1992), 775 777
  61. 61. Mallett S.V Cox D.J. 1992 Thrombelastography. Br J Anaesth, 69 3 (Sep 1992), 307 313
  62. 62. Mannucci P. M. Tripodi A. Bottasso B. Baudo F. Finazzi G. De Stefano V. Palareti G. Manotti C. Mazzucconi M. G. Castaman G. 1992 Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost, 67 2 (Feb 1992), 200 202
  63. 63. Mannucci PM. 1994 Mechanisms, markers and management of coagulation activation. Br Med Bull, 50 4 (Oct 1994), 851 870
  64. 64. Meissner MH Zierler BK Bergelin RO Chandler WC Manzo RA Strandness DE Jr. 2000 Markers of plasma coagulation and fibrinolysis after acute deep venous thrombosis. J Vasc Surg, 32 5 (Nov 2000), 870 880
  65. 65. Meltzer M.E. Lisman T. de Groot P. G. Meijers J. C. le Cessie S. Doggen C. J. Rosendaal F. R. 2010 Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood, 116 1 (Jul 2010), 113 121
  66. 66. Miller G. J. Bauer K. A. Barzegar S. Foley A. J. Mitchell J. P. Cooper J. A. Rosenberg R. D. 1995 The effects of quality and timing of venepuncture in markers of blood coagulation in healthy middle-aged men. Thromb Haemost, 73 1 (Jan 1995), 82 86
  67. 67. Monroe D. M. Hoffman M. 2006 What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol, 26 1 (Jan 2006), 41 48
  68. 68. O’Donnell J. Mumford A. D. Manning R. A. Laffan M.A. 2001 Marked elevations of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol, 115 3 (Dec 2001), 687 691
  69. 69. O’Donnell J. Riddell A. Owens D. Handa A. Pasi J. Hamilton G. Perry D. J. 2004 Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis, 15 3 (Apr 2004), 207 211
  70. 70. Palareti G. Legnani C. Cosmi B. Guazzaloca G. Pancani C. Coccheri S. 2002 Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost, 87 1 (Jan 2002), 7 12
  71. 71. Palareti G. Legnani C. Cosmi B. Valdré L. Lunghi B. Bernardi F. Coccheri S. 2003 Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation, 108 3 (Jul 2003), 313 318
  72. 72. Palareti G. Cosmi B. Legnani C. Tosetto A. Brusi C. Iorio A. Pengo V. Ghirarduzzi A. Pattacini C. Testa S. Lensing A. W. Tripodi A. PROLONG Investigators 2006 D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med, 355 17 (Oct 2006), 1780 1789 .
  73. 73. Papalambros E. Sigala F. Travlou A. Bastounis E. Mirilas P. 2004 P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment. J Am Coll Surg, 199 1 (Jul 2004), 69 77
  74. 74. Peternel P. Terbižan M. Tratar G. Božič M. Horvat D. Salobir B. Stegnar M. 2002 Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin. Thromb Res, 105 3 (Feb 2002), 241 246
  75. 75. Poli D. Antonucci E. Ciuti G. Abbate R. Prisco D. 2008 Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost, 6 4 (Apr 2008), 708 710
  76. 76. Poli D. Grifoni E. Antonucci E. Arcangeli C. Prisco D. Abbate R. Miniati M. 2010 Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis, 30 3 (Oct 2010), 294 299
  77. 77. Ramacciotti E. Blackburn S. Hawley A. E. Vandy F. Ballard-Lipka N. Stabler C. Baker N. Guire K. E. Rectenwald J. E. Henke P. K. Myers D. D. Jr Wakefield T. W. 2011 Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous Thrombosis. Clin Appl Thromb Hemost. 2011 May 17. [Epub ahead of print]
  78. 78. Rectenwald J. E. Myers D. D. Jr Hawley A. E. Longo C. Henke P. K. Guire K. E. Schmaier A. H. Wakefield T. W. 2005 D-dimer, P-selectin, and microparticles:novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost, 94 6 (Dec 2005), 1312 1317
  79. 79. Righini M. Perrier A. De Moerloose P. Bounameaux H. 2008 D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost, 6 7 (Jul 2008), 1059 1071
  80. 80. Rijken D.C. Lijnen H.R. 2009 New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost, 7 1 (Jan 2009), 4 13 .
  81. 81. Rosendaal F.R. 1999 Venous thrombosis: a multicausal disease. Lancet, 353 9159 (Apr 1999), 1167 1173
  82. 82. Schulman S. Lindmarker P. Holmström M. Lärfars G. Carlsson A. Nicol P. Svensson E. Ljungberg B. Viering S. Nordlander S. Leijd B. Jahed K. Hjorth M. Linder O. Beckman M. 2006 Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost, 4 4 (Apr 2006), 734 742
  83. 83. Schulman S. Wiman B. 1996 The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism: Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost, 75 4 (Apr 1996), 607 611 .
  84. 84. Siegemund A. Petros S. Siegemund T. Scholz U. Seyfarth H. J. Engelmann L. 2004 The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. Blood Coagul Fibrinolysis, 15 3 (Apr 2004), 241 244
  85. 85. Simioni P. Scarano L. Gavasso S. Sardella C. Girolami B. Scudeller A. Girolami A. 1996 Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol, 92 2 (Feb 1996), 435 441
  86. 86. Smith A. Quarmby J. W. Collins M. Lockhart S. M. Burnard K. G. 1999 Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost, 82 6 (Dec 1999), 1593 1599
  87. 87. Sorensen B. Johansen P. Christiansen K. Woelke M. Ingerslev J. 2003 Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost, 1 3 (Mar 2003), 551 558
  88. 88. Spiezia L. Marchioro P. Radu C. Rossetto V. Tognin G. Monica C. Salmaso L. Simioni P. 2008 Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. Blood Coagul Fibrinolysis, 19 5 (Jul 2008), 355 360
  89. 89. Stegnar M. Peternel P. Uhrin P. Cvelbar-Marinko T. Goršič-Tomažič K. Binder B. R. 1997 Fibrinolysis in patients with the 1691G-A mutation in factot V gene and history of deep vein thrombosis. Fibrinolysis Proteolysis, 11 4 (1997), 201 207
  90. 90. Stegnar M. Cuderman T. V. Božič M. 2007 Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability. Clin Chem Lab Med, 45 1 (2007), 40 46
  91. 91. Stegnar M. 2010 Thrombophilia screening-at the right time, for the right patient, with a good reason. Clin Chem Lab Med, 48 Suppl 1, (Dec 2010), S105 S113
  92. 92. Stricker H. Marchetti O. Haeberli A. Mombeli G. 1999 Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thromb Haemost, 82 4 (Oct 1999), 1227 1231
  93. 93. ten-Hoek Cate A.J Dielis A. W. Spronk H. M. van Oerle R. Hamulyák K. Prins M. H. ten Cate H. 2008 Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost, 100 2 (Aug 2008), 240 245
  94. 94. The DVTENOX Study Group. 1993 Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost, 70 6 (Dec 1993), 909 914
  95. 95. Tripodi A. Chantarangkul V. Martinelli I. Bucciarelli P. Mannucci P. M. 2004 A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 104 12 (Dec 2004), 3631 3634
  96. 96. Tripodi A. Legnani C. Chantarangkul V. Cosmi B. Palareti G. Mannucci P. M. 2008 High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost, 6 8 (Aug 2008), 1327 1333
  97. 97. van Hylckama Vlieg. A. Christiansen S. C. Luddington R. Cannegieter S. C. Rosendaal F. R. Baglin T. P. 2007 Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol, 138 6 (Sep 2007), 769 774
  98. 98. van Veen J. J. Gatt A. Makris M. 2008 Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol, 142 6 (Sep 2008), 889 903
  99. 99. Verhovsek M. JD Douketis Yi. Q. Shrivastava S. Tait R. C. Baglin T. Poli D. Lim W. 2008 Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med, 149 7 (Oct 2008), 481 490 .
  100. 100. Vižintin-Cuderman T. Božič-Mijovski M. Antović A. Peternel P. Kozak M. Stegnar M. Does the presence of thrombophilia modify hemostasis activation marker levels and overall hemostasis potential in patients treated for venous thrombosis? (to be published)
  101. 101. Wichers I. M. Tanck M. W. Meijers J. C. Lisman T. Reitsma P. H. Rosendaal F. R. Büller H. R. Middeldorp S. 2009 Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost, 101 3 (Mar 2009), 465 470
  102. 102. Wielders S. Mukherjee M. Michiels J. Rijkers D. T. Cambus J. P. Knebel R. W. Kakkar V. Hemker H. C. Béguin S. 1997 The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost, 77 4 (Apr 1997), 629 636
  103. 103. White R.H. 2003 The epidemiology of venous thromboembolism. Circulation, 107 23 Suppl 1, (Jun 2003), I4 I8

Written By

Tjaša Vižintin-Cuderman, Mojca Božič-Mijovski, Aleksandra Antović, Polona Peternel, Matija Kozak and Mojca Stegnar

Submitted: 07 February 2011 Published: 09 November 2011